Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research

October 19, 2022

https://www.globenewswire.com/news-release/2022/10/19/2537845/0/en/Larimar-Therapeutics-Announces-Oral-and-Poster-Presentations-at-the-Upcoming-International-Congress-for-Ataxia-Research.html

BALA CYNWYD, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich’s ataxia will be featured in three presentations at the upcoming International Congress for Ataxia Research. The conference will take place November 1 – 4, 2022, in Dallas, Texas.

Read more at globenewswire.com

Related news for (LRMR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.